REGN

In the past six months (April-October 2026), Regeneron Pharmaceuticals, Inc. (REGN) released strong Q1 and Q2 2026 earnings, with the Q2 report showing earnings per share (EPS) of $14.29 significantly exceeding consensus estimates and revenue of $4.29 billion surpassing forecasts, representing 16.7% year-over-year growth. This strong performance was driven by record quarterly sales for Dupixent, EYLEA HD, and Libtayo, alongside the full repayment of a development balance owed to Sanofi. Analyst sentiment has been broadly positive, with several research firms, including Truist Securities and JPMorgan Chase & Co., raising their price targets for REGN. Despite a modest pullback in early October 2026, the stock maintained a broader upward trend, having increased by approximately 31.20% over the last year.